Diagnostic potential of circulating cell-free nuclear and mitochondrial DNA for several cancer types and nonmalignant diseases: A study on suspected cancer patients

被引:6
|
作者
Sundquist, Kristina [1 ]
Sundquist, Jan [1 ]
Hedelius, Anna [1 ]
Memon, Ashfaque A. [1 ]
机构
[1] Lund Univ, Ctr Primary Hlth Care Res, Malmo, Sweden
关键词
biomarker; cancer; circulating DNA; diagnostic; mitochondrial DNA; nuclear DNA; PLASMA; ORIGIN;
D O I
10.1002/mc.23261
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Circulating cell-free nuclear DNA (nDNA) has been implicated in individual cancer types with a diagnostic value; however, the role of cell-free mitochondrial DNA (mtDNA) in cancers is controversial. We aimed to investigate and compare the diagnostic potential of both nDNA and mtDNA for multiple cancers and to investigate their ability to distinguish multiple cancers from healthy controls and from nonmalignant diseases. We also investigated the prognostic value of both nDNA and mtDNA. The absolute copy number of circulating DNAs in suspected cancer patients (n = 286) referred to a cancer diagnostic center and healthy controls (n = 109) was quantified by droplet digital polymerase chain reaction. Among the suspected cancer patients, 66 (23%) were diagnosed with various cancers, 193 (67%) with nonmalignant diseases, and 27 (10%) with no active disease. Levels of nDNA were significantly higher in cancers (copies/mu l; mean +/- SD, 21.0 +/- 14.2) as compared with nonmalignant diseases (15.2 +/- 10.0) and controls (9.3 +/- 4.1). In contrast, levels of mtDNA were significantly lower in cancers (copies/mu l; mean +/- SD, 68,557 +/- 66,663) and nonmalignant diseases (60,174 +/- 55,831) as compared with controls (98,714 +/- 77,789). Receiver operating curve analysis showed that nDNA not only could distinguish multiple cancers from controls (area under curve [AUC] = 0.78; 95% confidence interval [CI] = 0.70-0.86) but also from nonmalignant diseases (AUC = 0.68; 95% CI = 0.59-0.76). However, mtDNA could only differentiate cancers from controls (AUC = 0.65; 95% CI = 0.56-0.73). Higher levels of nDNA were also associated with increased mortality in the cancer patients (hazard ratio = 2.3; 95% CI = 1.1-4.7). Circulating cell-free nDNA, but not the mtDNA, could distinguish multiple cancers from nonmalignant diseases and was associated with poor survival of cancer patients.
引用
收藏
页码:1362 / 1370
页数:9
相关论文
共 50 条
  • [41] CIRCULATING CELL-FREE DNA IN ENDOMETRIAL CANCER.
    Cicchillitti, L.
    Corrado, G.
    De Angeli, M.
    Mancini, E.
    Baiocco, E.
    Chiofalo, B.
    Patrizi, L.
    Zampa, A.
    Piaggio, G.
    Vizza, E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 73 - 73
  • [42] Diagnostic Potential of Circulating Tumor Cells, Urinary MicroRNA, and Urinary Cell-Free DNA for Bladder Cancer: A Review
    Koguchi, Dai
    Matsumoto, Kazumasa
    Shiba, Izuru
    Harano, Takahiro
    Okuda, Satoshi
    Mori, Kohei
    Hirano, Shuhei
    Kitajima, Kazuki
    Ikeda, Masaomi
    Iwamura, Masatsugu
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (16)
  • [43] Circulating Cell-Free DNA-Diagnostic and Prognostic Applications in Personalized Cancer Therapy
    Oellerich, Michael
    Schuetz, Ekkehard
    Beck, Julia
    Walson, Philip D.
    THERAPEUTIC DRUG MONITORING, 2019, 41 (02) : 115 - 120
  • [44] Circulating Cell Free Nuclear DNA, Mitochondrial DNA and Global DNA Methylation: Potential Noninvasive Biomarkers for Breast Cancer Diagnosis
    Pasha, Heba A.
    Rezk, Noha A.
    Riad, Mohamed A.
    CANCER INVESTIGATION, 2019, 37 (09) : 432 - 439
  • [45] Efficacy of cell-free DNA as a diagnostic biomarker in breast cancer patients
    Iqra Khurram
    Muhammad Umer Khan
    Saooda Ibrahim
    Ayman Saleem
    Zaman Khan
    Muhammad Mubeen
    Arooj Khawar
    Qurban Ali
    Scientific Reports, 13
  • [46] Efficacy of cell-free DNA as a diagnostic biomarker in breast cancer patients
    Khurram, Iqra
    Khan, Muhammad Umer
    Ibrahim, Saooda
    Saleem, Ayman
    Khan, Zaman
    Mubeen, Muhammad
    Khawar, Arooj
    Ali, Qurban
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [47] Evaluation of circulating cell-free nuclear and mitochondrial DNA levels in Syrian patients with breast tumor
    Safi, Milda
    Najib, Abdul Rahman
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (01)
  • [48] Enhancing Diagnostic Evaluation of Patients with Symptoms of Lung Cancer Using the DELFI Circulating Cell-Free DNA Approach for Cancer Detection
    Leal, A.
    Mathios, D.
    Johansen, J. S.
    Lau, A.
    Jakubowski, D.
    Cristiano, S.
    Medina, J. E.
    Phallen, J.
    Larsen, K. R.
    Bruhm, D. C.
    Carey, J.
    Dracopoli, N. C.
    Maddala, T.
    Bojesen, S. E.
    Scharpf, R. B.
    Velculescu, V. E.
    Bach, P. B.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [49] Investigation of the Circulating Cell-free Mitochondrial DNA in Inflammation Related Neuromuscular Diseases
    Aydinoglu, Ayse Tulay
    Aksu-Menges, Evrim
    Bekircan-Kurt, Can Ebru
    Erdem-Ozdamar, Sevim
    Tan, Ersin
    Balci-Hayta, Burcu
    NEUROLOGY, 2023, 100 (17)
  • [50] Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool
    Pathak, Ashutosh K.
    Bhutani, Manisha
    Kumar, Sachin
    Mohan, Anant
    Guleria, Randeep
    CLINICAL CHEMISTRY, 2006, 52 (10) : 1833 - 1842